Drugs /

oregovomab

Back to Drugs List

Overview

NCI Definition [1]:
A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. (NCI04)

Clinical Trials

View Clinical Trials for oregovomab

Oregovomab has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating oregovomab, 1 is phase 1/phase 2 (0 open) and 1 is phase 3 (1 open).

BRCA1 Loss (germline), BRCA1 Mutation (germline), and BRCA2 Loss (germline) are the most frequent biomarker inclusion criteria for oregovomab clinical trials.

Fallopian tube adenocarcinoma, fallopian tube carcinoma, and fallopian tube clear cell adenocarcinoma are the most common diseases being investigated in oregovomab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Oregovomab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Oregovomab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating oregovomab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mab b43.13, monoclonal antibody b43.13, ovarex monoclonal antibody b43.13, ovarex, oregovomab, oregovomab, b43.13, moab b43.13, monoclonal antibody b43.13, moab b43.13, oregovomab (substance), ovarex, oregovomab (product)
Drug Target(s) [2]:
MUC16
NCIT ID [1]:
C1784
SNOMED ID [1]:
C-50209

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.